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Summary
Background. Reports on long-term outcomes after endoscopic axillary lymph node dissection (ALND) of breast
cancer patients are still lacking in the medical literature. The objective of this prospective study was to assess the
oncological and functional outcomes in breast cancer patients after endoscopic ALND.
Methods. Fifty-ﬁve breast cancer patients were prospectively enrolled, of whom 52 were available for follow-up
with a median of 71.9 months (range 11–96). The following oncological and functional endpoints were evaluated
during follow-up at several time points: occurrence of local, axillary and distant metastases, seroma or infection,
shoulder mobility (range of motion), numbness, pain, presence of lymphoedema as well as restriction in activities of
daily living.
Results. In 52 patients endoscopic ALND of level I and II was successfully performed. Two port-site metastases
(2/52, 4%) occurred, one of which in a patient with negative axillary lymph nodes. The same patient suﬀered from
the only axillary recurrence (1/52, 2%). Three patients (3/52, 6%) developed lymphoedema. No other functional
adverse events (shoulder mobility, pain, numbness, hypertrophic scar) were noticed at the end of the observation
period.
Conclusion. The present investigation with long-term follow-up after endoscopic ALND – the ﬁrst one in the
literature – reveals minor morbidity, good functional and cosmetic results. In contrary to conventional surgery, the
endoscopic procedure is associated with the occurrence of port-site metastases, not seen in the open approach.
Axillary recurrences do not appear more frequently when compared with results after conventional ALND. In the
meantime the less invasive sentinel lymph node (SLN) biopsy is the established standard technique in evaluating the
axillary lymph node status.
Introduction
Axillary lymph node staging represents an integral part
of the surgical procedure in breast cancer patients. It
provides important prognostic information and deter-
mines subsequent adjuvant therapy. Axillary clearance
minimizes axillary recurrence rates [1]. Educational
advertising, self-examination of the breast and screening
mammography favour the detection of breast cancer at
an early disease stage. Thus, the percentage of node-
positive patients who could beneﬁt from routine axillary
lymph node dissection (ALND) is constantly decreasing
[2]. The growing population of node-negative patients
should be spared a routine ALND with its considerable
short- and long-term sequelae [3]. Two diﬀerent mini-
mally invasive methods aiming to deﬁne the pathologi-
cal lymph node status with minimal morbidity were
evaluated in the nineties. Before the sentinel lymph node
(SLN) technique was initiated at our institution, we
adopted the endoscopic ALND of level I and II. The
SLN procedure was validated and established at our
department in 1997 [4]. Although the SLN procedure as
new axillary staging method in breast cancer patients
has gained increasing importance over the past years,
there are still surgeons and gynaecologists in Europe
who perform level I and II ALND either by open or
endoscopic approach. So far no long-term results after
endoscopic ALND in breast cancer patients are avail-
able. The objective of the present prospective study was
to evaluate long-term oncological and functional out-
comes in breast cancer patients after endoscopic ALND.
Patients and methods
Between January 1996 and June 1998, 55 women with
primary breast cancer stage I and II were prospectively
enrolled (Table 1). Exclusion criteria were: suspicious
axillary lymph nodes and a tumour in the axillary tail in
close vicinity to the axilla that was to be inﬂated.
Written informed consent was obtained from all pa-
tients.
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Technique of endoscopic ALND
The technique of endoscopic ALND has been described
elsewhere [5–8]. Brieﬂy, the patients were placed in a
supine position with the ipsilateral arm in a 90 degree
abduction. The axillary fat pad was inﬁltrated with 250–
450 ml of liposuction ﬂuid, depending on the amount of
axillary fat. The liposuction ﬂuid consisted of 500 ml of
0.45% sodium chloride with 10 ml of 4% lidocaine and
5 mg adrenaline. During the ongoing axillary lipolysis
process, tumourectomy was performed. Thereafter, the
liposuction canula was introduced through an incision
of 10–15 mm in the middle axillary line. Aspiration was
achieved with a vacuum of 800 mbar. A ﬁrst 10 mm
trocar was then introduced through the existing incision.
After insuﬄation of CO2 gas with a pressure of 8 mmHg
two additional 5 mm trocars were placed, one in the
anterior and another in the posterior axillary line. The
25 degree angled 10 mm optic was used. The axillary
lymph nodes of level I and II were dissected and re-
moved through the 10 mm trocar after changing to a
5 mm optic. The optic, all trocars, and the endoscopic
instruments were reusable and taken from the laparos-
copy instrumentation box. No speciﬁc adaptations were
necessary. At the end of the intervention the liposuction
ﬂuid was ﬁltered through a gauze and the retrieved
lymph nodes were sent separately for histopathology.
All operations were carried out by one surgeon (F.H.)
Pathologic examination of lymph nodes
Excised and ﬁltered lymph nodes were examined sepa-
rately. Lymph nodes larger than 5 mm in diameter were
bisected, whereas lymph nodes less than or equal to
5 mm in diameter were entirely submitted. Lymph nodes
were formalin-ﬁxed and embedded in paraﬃn for his-
tologic analysis. Two sections were performed on the
larger lymph nodes (one section on each half) whereas
the smaller nodes were cut only once. The sections were
stained with Haematoxylin & Eosin (H&E). No step
sections or immunohistochemistry were performed.
Adjuvant therapy
After breast-conserving surgery patients received post-
operative radiation therapy with 45 Gray over 5 weeks
with an additional boost of 10 Gray to the tumour site,
which was intraoperatively marked with a titanium clip.
No radiation therapy was applied to the axilla. Systemic
Table 1. Patients and tumour characteristics
Parameters All patients (n = 55)
No. %
Age (Years)
Median 58.0
Range 30–86
Menopausal status
Premenopausal 12 21.8
Postmenopausal 43 78.2
Tumour size in mm
Median 20
Range 5–50
T stage
T1a 2 3.6
T1b 5 9.1
T1c 21 38.2
T2 27 49.1
N stage
NO 37 67.3
N+ 18 32.7
Table 1. (Continued)
Parameters All patients (n = 55)
No. %
No of lymph nodes resected
Median 13
Range 5–25
Additional lymph nodes
in liposuction
Median 1
Range 0–9
N+ in liposuction 4/52 7.7
Histology
Ductal 42 76.4
Lobular 8 14.5
Other 5 9.1
Histological grading
G1 8 14.5
G2 29 52.8
G30 18 32.7
Primary tumour
Tumourectomy 26 47.2
Mastectomy 29 52.8
Quadrant
Upper outer 31 56.4
Upper inner 5 9.1
Lower outer 5 9.1
Lower inner 7 12.7
Areolar 7 12.7
Estrogen receptor status
Positive 40 72.7
Negative 15 27.3
Progesteron receptor status
Positive 36 65.5
Negative 19 34.5
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treatment was based on the recommendations of the
1996 St. Gall Consensus Conference [9]. Adjuvant
therapy consisted of hormonal treatment (Tamoxifen
for 5 years: 20 mg daily) and/or chemotherapy (Adria-
mycin + Cyclophosphamide or Epirubicin + Cyclo-
phosphamide) every 3 weeks for a total of 12 weeks. In
low-risk patients, elderly patients, and patients with
contraindications for anthracyclines, six cycles of CMF
(Cyclophosphamide + Methotrexate + 5-FU) were
administered.
Postoperative follow-up
Postoperative follow-up consisted of a clinical exami-
nation of the breast and axilla every 4 months for the
ﬁrst 3 years, every 6 months in the following 2 years and
yearly thereafter. Subjective criteria such as pain,
numbness, and restrictions in daily life activities due to
scarring or complaints in the arm were assessed.
Objective criteria included the pre- and postoperative
measurements of (1) range of motion in all directions of
the shoulder according to the neutral zero crossing
method; (2) the circumferences of both upper extremities
15 cm above and 10 cm below the olecranon and (3) the
dexterity to bind an apron at the neck and the back. A
deﬁcit in range of motion greater than 20 degrees to
standard values was considered pathologic. The diag-
nosis of lymphoedema was made if at least one of the
following three criteria were present (subjective symp-
toms, objective ﬁndings, and asymmetric ipsi- and con-
tralateral measurements). Symptoms like swelling and
heaviness of the aﬀected arm were considered diagnostic
as well as clinical ﬁndings like indentation following skin
depression, a loss of skin folds and asymmetry of the
extremities. A 2 cm increase in one of the circumferences
compared with the ipsilateral baseline measurements
was considered pathologic. Furthermore, a 2 cm in-
crease in circumference compared to the contralateral
side was regarded as pathologic. For this purpose the
handedness was noted, a 1 cm preoperative diﬀerence in
favour of the dominant arm was considered normal.
Consequently, values exceeding 1 cm were calculated to
the postoperative measurement results.
At 24 months of follow-up a standardized question-
naire was sent to all patients assessing pain in the upper
and lower arm, in the breast and chest wall, shoulder
mobility, and restrictions in activities of daily living.
Mammographies were performed annually. Breast
ultrasound was only made for clariﬁcation of suspicious
mammographic ﬁndings. Data were analyzed at 6 weeks
after surgery (deﬁned as early postoperative events) and
during follow-up at a median of 24 and 71 months
postoperatively.
Results
The patient characteristics are listed in Table 1. Endo-
scopic ALND of level I and II was completed in 52 of 55
breast cancer patients (95%). Endoscopic ALND was
converted to conventional open ALND in three patients
due to bleeding of the thoracodorsal vein (n ¼ 1), to an
exceedingly fatty axilla not enabling proper identiﬁca-
tion of important anatomical landmarks (n ¼ 1), and to
ﬁbrotic changes of the axillary fat pad after neoadjuvant
chemotherapy (n ¼ 1). According to the intention-to-
treat principle these patients were also included in all
analyses and remained tumour-free. Operating time for
endoscopic ALND and removal of the primary tumour
ranged from 95 to 240 min with a median of 135 min.
We retrospectively compared the operating time of pa-
tients undergoing endoscopic axillary dissection to a
group of 52 breast cancer patients with matched char-
acteristics regarding tumour size and age receiving
conventional ALND. All operations were performed by
the same surgeon (F.H.) 1 year prior to starting the
endoscopic axillary dissection. The operating time for
conventional ALND and removal of the primary tu-
mour ranged from 40 to 205 min with a median of
80 min whereas the endoscopic approach required on
average 55 more minutes. This diﬀerence in operating
time was statistically highly signiﬁcant (p < 0.0001;
Mann–Whitney U-test).
A median number of 13 (range: 5–25) axillary lymph
nodes were removed during the 52 successfully per-
formed endoscopic procedures. Additionally, an average
of one lymph node (range 0–9) per patient was found in
the ﬁltered liposuction ﬂuid. Sixteen of 52 patients
(30.8%) had lymph node metastases. Four patients had
metastatic nodes in the ﬁltered ﬂuid. In two of them
these nodes were the only metastatic ones.
Systemic adjuvant treatment consisted of hormonal
therapy in 30/52 patients (57.6%), of chemotherapy only
in 13/52 patients (25%) and of combined treatment in 8/
52 patients (15.4%). One patient (2%) did not receive
any systemic therapy.
At 6 weeks postoperative complications occurred in
10/52 (19%) patients. Eight patients (15%) developed
an axillary seroma and underwent one or several needle
aspirations. Injury to the thoracodorsal nerve resulted in
a persistent winged scapula in one patient (2%). A low
grade infection of the axilla occurring in one patient
during adjuvant chemotherapy was successfully treated
with antibiotics (2%). The patients were discharged
after a median of 5.6 days (1–16 days).
Three patients were lost to follow-up who were ex-
cluded from the analyses due to lack of information.
Eight patients died at a median of 34.0 months (range
10.6 to 67.4 months) post surgery. Death was related to
metastatic disease in four patients (bone, liver, brain and
lung), two of whom were node-positive at the time of
surgery, another patient showed a high grade pT2 tu-
mour and the last was a premenopausal woman with a
pT2 G2 carcinoma. One patient died of leukaemia, and
three deaths were due to other, non-oncological causes.
Furthermore, two patients developed bone metastases,
one of them being initially node-positive. Local breast
recurrence occurred in one patient (1/52, 2%).
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In two patients histologically conﬁrmed port-site
metastases were detected at 24 and 49 months after
endoscopic ALND, respectively (2/52, 4%). Diagnosis
was histologically conﬁrmed after excision of the af-
fected axillary skin. One of these postmenopausal wo-
men was node positive at the time of the initial
operation (9 of 17 positive lymph nodes) staged as a
pT2G2 invasive ductal carcinoma. After excision of the
port-site metastasis at 24 months, distant metastatic
disease to the liver occurred. The patient died one year
later. In the second patient with pT2G3 invasive lobular
carcinoma, all 11 endoscopically removed lymph nodes
were free of metastases. Simultaneously with the port-
site metastasis this patient developed the only axillary
recurrence (1/52, 2%) found in our study population.
The recurrence was surgically removed. Three years la-
ter, the patient is still alive and without evidence of
recurrent local or metastatic disease.
The questionnaire was ﬁlled out by 52 patients at a
median of 24 months (range 7–37 months) postopera-
tively. On a scale between 1 (worst) and 10 (excellent)
the patients noted median values for pain in the upper
and lower arm, pain in breast and chest wall, shoulder
mobility, and restrictions in activities of daily living
between 9.2 and 9.9 (Table 2). At physical examination
at the same time point two patients suﬀered from
restricted shoulder mobility with an anteversion deﬁcit
of 20 degrees and abduction deﬁcit of 30 degrees.
Twelve of 52 patients (23%) indicated shoulder pain at
abduction and anteversion movement and 9/52 patients
(17%) superﬁcial pain in the dorsomedial skin area of
the aﬀected upper arm. Three patients (6%) com-
plained of numbness of the upper arm. No lymphoe-
dema was detected at that stage (Table 3).
Median follow-up for the 52 patients was
71.9 months ranging from 11 to 96 months. Other than
noted in the questionnaire no relevant numbness or
hypertrophic scar were observed on clinical work-up.
Shoulder pain (n ¼ 12) and pain in the upper arm
(n ¼ 9), which were present at the ﬁrst evaluation after a
median of 24 months postoperatively, disappeared
completely during further follow-up. No increase in
functional restrictions of the shoulder regarding range of
motion was noticed. At the last follow-up examination
three patients (6%) had developed lymphoedema with
an increase in circumference of 3–4 cm in the upper and/
or lower arm. None of the three patients suﬀered from
recurrent axillary or distant disease, none complained of
chronic pain or restriction in range of motion and in
daily life. The number of lymph nodes removed in these
patients were 12, 16 and 21, respectively. Two of these
patients were node-positive at the time of operation with
1/21 and 3/12 positive lymph nodes, respectively
(Table 3).
Discussion
The present investigation with long-term follow-up after
endoscopic ALND – the ﬁrst one reported in the liter-
ature – reveals minor morbidity, good functional and
cosmetic results after endoscopic ALND. The endo-
scopic procedure shows a low axillary recurrence rate as
one can expect after open level I and II ALND. But the
endoscopic ALND carries a risk of port-site metastases.
The clinical and prognostic impact of port-site metas-
tases is unknown.
Our study provides compelling evidence that endo-
scopic ALND is advantageous regarding long-term
functional results such as shoulder mobility and chronic
pain when compared with conventional ALND [10]. The
occurrence of moderate lymphoedema in 6% in the
present investigation is lower than in the majority of
Table 2. Self evaluation questionnaire (n = 51 patients)
Subjective valuea
Median Range
Pain upper arm 9.4 4–10
Pain lower arm 9.9 6–10
Pain chest wall/breast 9.2 6–10
Shoulder range of motion 9.4 4–10
Use of arm in daily life 9.5 5–10
a Score 1–10: 1 – very bad; 10 – excellent.
Table 3. Morbidity and mortality at diﬀerent time points (n = 52
patients)
Time points 6 weeks 24 (7–37)
monthsa
72 (11–96)
monthsa
n % n % n %
Axillary seroma 8 15.4 0 0
Winged scapula 1 1.9 1 1.9 1 1.9
Axillary
infection
1 1.9 0 0
Shoulder
restriction
NA 2 3.8 0
Shoulder pain NA 12 23.1 0
Upper arm pain NA 9 17.3 0
Numbness NA 3 5.8 0
Hypertrophic
scar
NA 3 5.8 0
Lymphoedema 0 0 3 5.8
Loss to
follow-up
0 1 1.9 3 5.8
Axillary
recurrences
0 1 1.9 1 3.8
Port-Site
metastases
0 1 1.9 1 1.9
Distant
metastases
0 5 9.6 7 13.5
Death 0 3 5.8 8 15.4
NA – not assessed
a Median value (range)
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investigations assessing the morbidity of conventional
ALND. Indeed, the incidences of lymphoedema after
open axillary dissection are described between 5 and
25% [1, 11–16]. Although there are generally accepted
criteria but not well-established guidelines to diagnose
lymphoedema using circumferential measurements,
there are no universally applied methods to quantitatively
deﬁne lymphoedema and no standard degree of enlarge-
ment or consensus, what constitutes lymphoedema,
thereby complicating interpretation of the literature [17].
There are reports citing that a greater than 2 cm diﬀerence
from baseline (preoperative) measurements identiﬁes
lymphoedema [18]. On the other hand girthmeasurements
do not always correlate with symptoms or quality of life
[19]. A combination of symptom assessment and limb
measurement may provide the best clinical assessment
data for identifying changes associated with post-breast
cancer lymphoedema [20, 21]. In a retrospective study
from our institution including 390 breast cancer patients
undergoing ALND lymphoedema of the upper and lower
arm were found in 13.2 and 8.4%, respectively, after a
median follow-up of 62 months [10]. In the afore-men-
tioned investigation, numbness was seen in 28%, hyper-
trophic scar in 17%, and shoulder pain in 15% of all
patients, clearlymore frequently than in the present study.
Oncological safety might, however, be compromised as
port-site metastases occurred in two patients (4%), one of
whom suﬀered concomitantly from an axillary recurrence
(2%). Current medical literature describes a similar ax-
illary recurrence rate between 0 and 2%after openALND
[22]. In the abovementioned study from our institution an
axillary recurrence rate of 1.3% after standard ALND of
level l and II was observed [10]. Skin implantation
metastasis after openALND is an unknown adverse event
and has never been published before. The prognostic
signiﬁcance of port-site metastases after endoscopic
ALND for breast cancer is unclear. Port-site metastases
are a known phenomenon in laparoscopic surgery for
abdominalmalignancies.Wexner reported an incidence of
4% in laparoscopic colorectal surgery for cancer [23].
Port-site metastases correlated with shortened survival in
ovarian and gallbladder cancer [24].
Endoscopic ALND oﬀers several advantages com-
pared with conventional ALND. It provides an excellent
view of the various important anatomical structures,
Figure 1. (a) Anatomical axillary landmarks and important structures
after dissection: * long thoracic nerve; ** thoracodorsal nerve and
vascular bundle. (b) Endoscopic axillary lymph node dissection after
liposuction.
Table 4. Morbidity after endoscopic ALND – a comparison with the literature
Salvat et al.
[32]
Suzanne et al.
[5]
Brun et al.
[26]
Kamprath et al.
[28]
Kuehn et al.
[27]
Present
study
Year 1996 1997 1997 1999 2001 2004
No. of patients 20 72 43 33 53 52
Seroma (%) 15 3 9 9 24 15
Wound infection (%) 5 – 2.3 3 1.9 1.9
Winged scapula (%) – – – 3 – 1.9
Lymphoedema (%) NA 2.8 – NA 3.6 7.3
Axillary recurrence 2 – – – – 1
(10%) (2%)
Port-site metastases – – – – – 2
(4%)
Length of follow-up
(months)a
NA 18b 18 4.6 – 71.9
(12–27) (1–9) (7–21) (11–96)
a Values are median or bmean, NA – not assessed
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which can be easily preserved during the intervention
(Figure 1a and b). Bleeding can be stopped precisely and
incisions are smaller and thus the trauma to the tissue is
reduced [8]. The number of retrieved lymph nodes is
similar compared with open ALND and provides ada-
equate information of the lymph node status [5, 10, 25–
27]. In the current literature, the occurrence of postop-
erative seroma formation appears to be reduced (3–
24%), cosmetic results to be better and functional out-
comes improved compared with conventional ALND [5,
8, 10, 28]. Maunsell et al. assessed 223 patients 3 months
after open level I and II dissection. They reported that
82% of patients suﬀered from at least one arm problem,
including swelling (24%), weakness (26%), limited arm
movement (32%), stiﬀness (40%), pain (55%), and
numbness (58%). No signiﬁcant decrease of these
symptoms was observed after 18 months post surgery
[29]. Warmuth et al. found a 55% rate of patients suf-
fering from at least one adverse outcome 2–5 years after
conventional ALND of level I and II. Thirty-ﬁve per-
cent reported numbness of the upper arm, 30% pain in
the axilla, breast or chest, 15% arm swelling, and 8%
limited shoulder or arm movement [30]. Roses et al.
described a 76.5% rate of postoperative pain and
numbness in his patient collective with a complete res-
olution in 22% and an improvement in 57% of those
cases after a median follow-up of 38.5 months [31].
These ﬁndings correspond well with the results of the
present study, as pain in the shoulder joint and upper
arm resolved completely during long-term observation.
Disadvantages of the technically demanding endo-
scopic ALND compared with the open procedure in-
clude longer operating times and higher material
expenses [25, 27, 32]. Moreover, the signiﬁcantly in-
creased operating time, in our investigation almost 1 h,
further contributes to higher costs. Material expenses in
our group of patients were very low because reusable
trocars and already available laparoscopic instruments
were used and no speciﬁc adaptations were necessary.
Finally, and most importantly, endoscopic ALND ig-
nores the general surgical oncological principle of
en-bloc resection of potentially tumour-involved lymph
nodes. The port-site metastases in two of our patients –
the ﬁrst description in the literature after endoscopic
ALND – could result from violation of this principle. In
other published series with shorter follow-up times
(median follow-up shorter than or equal to 18 months)
axillary recurrences after endoscopic ALND occurred
between 0% [32] and 10% [5, 26, 27, 32] (Table 4). The
two axillary failures published in the paper of Salvat
et al. were both observed in patients with primarily
extensive lymph node involvement [32].
Conclusion
Endoscopic ALND is associated with minor morbidity,
good functional and cosmetic results. However, the
endoscopic procedure carries the risk of port-site metas-
tases. The axillary recurrence rate is similar to the results
after conventional open ALND. Based on previous
assessments of our SLN data and the current literature,
the SLN biopsy is amore adapted, less invasive technique
and should be considered the preferred axillary staging
procedure.
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